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SUMMARY 
While numerous studies of aldosterone r8glucuronide excretion in pregnancy 
have been published few data have been available about the other major catabolite of 
aldosterone, the 3cc,$?-tetrahydro derivative. 
Tetrahydroaldosterone, measured by gas chromatographic techniques, is higher 
in the luteal phase than in the follicular phase of nonpregnant young women. A wide 
range in tetrahydroaldosterone excretion was noted in pregnant subjects on unre- 
stricted salt intake at the same stage of gestation. While some values remained at 
those levels encountered during the menstrual cycle, even in the last trimester of 
pregnancy, the average excretion generally rose with added weeks of gestation. The 
increases in tetrahydroaldosterone excretion are smaller than those reported by other 
workers for the r8-glucuronide aldosterone metabolite, supporting the suggestion 
made by I<. M. Jones, R. Lloyd-Jones, A. Riondel, J. I;. Tait, S. A. S. Tait, R. D. 
Bulbrook and F. C. Greenwood (Acta Edocrinol., 30 (1939) 321), as well as by J. F. 
Tait and B. Little (J. C&n. Invest., 47 (1968) 242x), that aldosterone metabolism is 
altered in pregnancy. 
INTRODUCTION 
For a number of years, it has been known that aldosterone production is in- 
creased in pregnancy. Elevated secretionlp2 and excretion3 of the hormone have been 
reported. More recently, Weir and associates4 reported an increased plasma aldosterone 
concentration in normal pregnant women. From the reports of Laidlaw et al.5, who 
detected very low urinary excretion of aldosterone by two bilaterally adrenalectomized 
women during pregnancy, and of Baulieu et aLs, who found no aldosterone in the 
urine of a pregnant woman with Addison’s disease, it has been assumed that in 
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humans the origin of aldosterone is adrenal rather than placental. However, Pasqualini 
et aL7 and Dufau and Villee* have reported that the adrenal cortex of human fetuses is 
able to convert progesterone to aldosterone in vitro. Bayard et al.8 infused radio- 
actively labelled aldosterone intravenously into mothers before delivery, subsequently 
detected the labelled steroid in fetal blood, and thus demonstrated the ability of 
aldosterone to cross the placenta. Assuming that equilibration had been reached during 
the infusion, they also concluded that, since the specific activity of aldosterone was 
less in fetal than in maternal blood, fetal secretion of aldosterone before birth was 
demonstrated. 
The aldosterone secreted by the adrenal gland is found in urine in three forms : 
free aldosterone, aldosterone released from the acid labile conjugate, presumed to be 
aldosterone 1%glucuronide, and tetrahydroaldosterone glucuronide. The first two 
compounds have been measured in pregnancy1p3, on both unrestricted and controlled 
sodium intakes. However, to our knowledge, no report has been published on the 
urinary excretion of the tetrahydro metabolite by normal pregnant women. Hence, 
the present study was undertaken to determine the urinary levels of 3n,$-tetra- 
hydroaldosterone (THA) in women with uncomplicated pregnancies on normal un- 
restricted sodium intakes. A modification of the techniques of Nicolis et ~Z.l~*~l using 
gas-liquid chromatography (GLC) with electron capture detection was used to quanti- 
tate the THA. 
MATERIALS AND METHODS 
Subjects 
Twenty-three normal pregnant women, ranging in age from 17 to 36 years were 
studied. The gestation time of the pregnancy was estimated from the first day of the 
last normal menstrual period. The subjects were divided into first, second and third 
trimester groups. 
Ten normal nonpregnant female control subjects were in the age range 20-26. 
Five were in the follicular phase and five in the luteal phase of their menstrual cycles. 
Seven normal young men, between the ages of 19 and 31 were also studied. 
All of the subjects, pregnant and nonpregnant, were ambulatory, and their 
dietary intake of sodium was unrestricted since the object of the study was to follow 
variations in THA secretion as it actually occurs in representative American pregnan- 
cies. 
Urine was kept cold during the collection period, and no preservative was added. 
Completeness of the collection was monitored by creatinine determinations. 
Reagents 
Benzene, ethyl acetate and acetone were nanograde and used without further 
purification. Other solvents were of reagent grade and distilled twice through all- 
glass fractionating columns. 
d-[I+3H]Aldosterone, specific activity 42 Ci/mM and [I,z-~H]THA, specific 
activity 32 Ci/mM, were obtained from New England Nuclear, and purified by thin- 
layer chromatography (TLC) before use. Standard THA y-lactone was prepared by 
enzymatic reduction of d-aldosterone y-lactone ll. The method described by Tomkin+ 
was used to prepare the appropriate $-reductases. 
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The etiolactones of THA and IS-hydroxytetrahydrocorticosterone used for ref- 
erence, were kindly donated by Dr. Stanley Ulick. Nonradioactive d-aldosterone was 
purchased from Sigma. The heptafluorobutyric anhydride was obtained in 1.0 ml 
pre-scored ampules (Pierce Chemical Company, Rockford, Ill. U.S.A.) and stored in a 
desiccator. 
PlatesforTLC(Brinkmann Instruments Incorporated, Westbury, N.Y., U.S.A.) 
were 5 x 20 cm and precoated with 0.25 mm of Silica Gel F-254. To remove impurities 
they were washed with methanol, then stored in a cabinet desiccator. 
Tritium was counted in a Packard Tri-Carb liquid scintillation spectrometer 
Model 3310. The scintillation fluid was prepared with 4.0 g of PPO, IOO mg of BBOT 
(Packard Instruments Company) in I 1 of toluene. 
Following chromatography, the plates were scanned for radioactivity on a 
Packard Radiochromatogram Scanner Model 7201. 
The GLC estimation was carried out on an F & M (Hewlett-Packard) Model 402 
instrument equipped with a Nickel-63 electron capture detector. A 3-foot, 0.4 mm 
internal diameter, U shaped, glass column, packed with 1% XE 60 on Gas Chrom Q, 
80-100 mesh (Applied Science Lab) was conditioned for 3 days before use. Argon 
with 5% methane, which was passed through a molecular sieve before entering the 
column was used as the carrier gas. 
The conditions at the time of analysis were : column 230’, detector 290’ ; carrier 
gas flow 85 ml/min. Samples were injected on the column with a IO-pl Hamilton 
syringe. 
Procedwe for the isolation of THA from wine 
The method involves the following steps : hydrolysis, extraction, periodic acid 
oxidation of THA, TLC of the lactone of THA, formation of the heptafluorobutyrate 
derivative, TLC of this compound, followed by gas chromatography. Initially, another 
TLC was performed before the oxidation of THA. However, when the results of the 
three TLC were compared with those obtained by two TLC procedures, no significant 
difference was found. 
Approximately 80000 cpm of purified [I,~-~H]THA are added to 1% of a 24-h 
urine collection, which is incubated with IOOO U/ml of a mixture of c+glucuronidase 
and sulfatase (glusulase), for 24 h, at 45” and pH 5. The samples may also be incubated 
at 37O for a period of 48-63 h without any change in results. After hydrolysis, the 
samples are filtered (this maneuver was found to be critical in preventing emulsion 
formation), and three extractions with I volume of ice-cold ethyl acetate are carried 
out. The extracts are pooled and washed three times with 4 ml of 0.2 N NaOH, and 
then with water, followed by evaporation to dryness in a flash evaporator at 35-40~. 
The residue is transferred to a conical stoppered tube with the aid of 6-8 ml of 
nanograde ethyl acetate. After evaporation under nitrogen, the samples are oxidized 
with periodic acid as described by Nicolisll, and extracted three times with 2 ml of 
methylene chloride. The combined extracts are washed three times with 1.5 ml of 
1.0 N NaOH, three times with 2.0 ml of water, and again evaporated to dryness under 
nitrogen. To separate the products from the reaction mixture, TLC is performed in 
the system ethyl acetate-benzene (6:4, v/v). THA y-lactone, RF 0.30, separates from 
THA, which remains at the origin. The y-lactone derivative is located by scanning 
and eluted with acetone. 
After evaporation of the solvent the formation of the heptafluorobutyrate 
derivative is carried out by incubating each sample with 2.0 ml of 1% heptafluoro- 
butyric anhydride and 0.5% tetrahydrofurane in benzene at 60” for 43 min. Samples 
are thoroughly dried under nitrogen, and then chromatographed on thin layer plates, 
which are developed in the system benzene-ethyl acetate (95:5, v/v). The zone con- 
taining the final derivative, RF 0.44, is eluted with 2.0 ml of benzene-ethyl acetate 
(I : I, v/v). The zone to be eluted is defined as comprising 8 mm on either side of the 
radioactive peak. The solvent is again evaporated under nitrogen, 
Before GLC, samples are dissolved in 0.025-0.5 ml of benzene and 2-5 ,ul are 
injected into the gas chromatograph, and a suitable aliquot is added to scintillation 
fluid and counted to assess the recovery obtained throughout the purification steps. 
Standard curves are routinely obtained before and after injection of the samples. 
It has been found convenient to monitor the sensitivity of the instrument occasionally, 
by injecting a known amount of pure THA y-lactone heptaflurobutyrate standard 
among samples. Should the sensitivity change, another standard curve is obtained 
before proceeding with the analysis of samples. 
RESULTS 
Precision was evaluated on the basis of the coefficient of variation of duplicate 
determinations of samples derived from 12 subjects. It was of the order of 4.0% with 
a standard deviation of 3.5%. In a separate series of studies the reproducibility of the 
method using z as compared to 3 thin layer chromatograms was determined. Again 
for a series of urines from 12 subjects, this was found to be 6.1 f 6.7%. 
Recovery of [3H]THA added as a tracer was found to be 27.4 * 8.80/, (standard 
deviation). It is, therefore, necessary to correct final values routinely for the recovery 
of added internal standard. In addition, of course, the radioactive tracers are used for 
locating the appropriate compounds after TLC. 
The use of the heptafluorobutyrate derivative of THA II-lactone, allows the 
measurement of extremely small amounts of the steroid by GLC with electron 
capture detection. In our hands, under the conditions described, the smallest amount 
which could be quantitated accurately without using the maximum sensitivity of the 
G.C. was 0.10 ng. In practice, however, it was not necessary to work with such small 
amounts; generally, the standard curve was obtained by injecting 0.5, 1.0, 1.5 and 
2.0 ng of pure standard. Because the sensitivity is high, only small amounts of urine 
need to be worked up. This facilitates handling and yields better recoveries in the 
periodic acid oxidation step and the formation of the heptafluorobutyrate derivative 
than the use of 50 ml or more of urine. 
The heptafluorobutyrate-THA lactone peaks obtained from urine extracts 
have the same retention time as those of pure heptafluorobutyrate-THA lactone 
standard. Water blanks taken through the entire procedure gave no peak in the deriva- 
tive region. The likeliest interference, I8-hydroxytetrahydrocorticosterone, was shown 
to have a different retention time (11.5 min) in the column used. The results for con- 
trol subjects are in good agreement with values previously reported by other in- 
vestigator+‘. Finally Nicolis et aLlo used infra-red spectrophotometry and a rather 
similar system involving TLC and acetylation with monochlorodifluoracetic anhydride 
showed identity between the product obtained from urine and authentic standards. 
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THA urinary excretion in normal men and women 
THA excretion by seven normal male subjects on an uncontrolled diet ranged 
from 12 to 36 ,ug per day, with a mean of 21 pg (Fig. I). 
The 24-h urinary excretion of THA was measured in ten nonpregnant women on 
a free salt intake. Five were in the follicular phase and five in the luteal phase of their 
menstrual cycles. The aim was to determine whether there were changes in the THA 
excretion rate during this period. It is evident (Fig. I) that there was a significant rise 
in the THA excretion during the luteal as compared to the follicular phase, the mean 
THA excretion of 66 pg per day during the former period being almost double the 
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THA excretion in normal pregnant subjects 
A wide range in THA excretion was noted in different subjects at the same stage 
of gestation. Fig. z shows the THA excretion measured in II subjects from weeks 9 to 
13 of gestation. While three subjects in this group showed a significant elevation in 
THA excretion, most of the subjects remained within the range of values found in the 
series of nonpregnant women. The mean value of 90 kg/day for that group is somewhat 
higher than the THA excretion of the nonpregnant women in the luteal phase of the 
menstrual cycle. The values found for 16 determinations in eight subjects from weeks 
16 to 27 are shown in the same figure. In this group IO values are either slightly or 
markedly elevated above the normal range. The mean value of 105 pg/day found in 
this group is again higher than that of nonpregnant women or of the first trimester 
group. The women pregnant from weeks 28 to 40 showed the highest THA excretion 
with a mean for 21 determinations in 13 subjects of 166 pg/day. However, four values 
were still within the range of the nonpregnant women in the follicular phase. 
Serial determinations of THA excretion in three pregnant subjects are shown 
in Fig. 3. In all three subjects, there was considerable fluctuation in THA excretion 
measured during the progression of pregnancy. In subjects G.C. and D.F., a fall in 
THA excretion was noted near term, but subject D.C. demonstrated a rise in THA 
excretion at 39 weeks. In all three the values shortly after delivery were lower than 
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Fig. L. THA excretion in uncomplicated pregnancy. The first group of closed triangles corresponds 
to subjects in the first trimester, the open triangles to those in the second trimester and the last 
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DISCUSSION 
The increase in THA excretion reported here during the luteal as compared to 
the follicular phase of the menstrual cycle parallels reports by other workers who 
measured aldosterone Sglucuronide excretion. Thus Haines et a1.13 found ameanvalue 
of 5.8 pg per day of aldosterone I8-glucuronide (range 2.8-7.5) during the follicular 
phase and 9.7 pu,g (range z.o-zz) during the luteal phase. The increase in THA ex- 
cretion also correlates with the rise of aldosterone secretion rate in the luteal phase 
observed by Gray et al.14 who reported values for aldosterone secretion rates of 139 
and 235 ,ug per day during the follicular and luteal phase, respectively. 
The urinary excretion, and secretion of aldosterone have been reported to be 
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increased in normal pregnancy1-3. More recently, plasma aldosterone concentration 
was found to be elevated in normal, gravid subjects on unrestricted diets4. It is also 
known that aldosterone secretion in normal pregnant women, as in nonpregnant sub- 
jects, is inversely related to sodium intake, the highest values being observed in sub- 
jects receiving a sodium diet of less than IO mequiv/day2. Despite the large amount of 
data on the increased secretion and excretion of aldosterone by normal pregnant 
women, the mechanisms responsible for this elevation are still not well understood. 
Several factors that may play a role in the enhancement of aldosterone production 
during pregnancy have been suggested. First, it is well known that during pregnancy 
the sodium load which is filtered is increased. Also there is sodium retention’s re- 
quired to meet the needs of the developing products of conception. However, neither 
of these factors have provided a really satisfactory explanation for the great increase 
in aldosterone secretion2. 
Progesterone has natriuretic activity, due to competitive inhibition of aldo- 
sterone action on the distal renal tubule16. Biglierir7 reported a case of primary aldo- 
steronism in a woman, who showed a marked improvement of the manifestations of 
the disease during pregnancy; this amelioration was attributed to the antialdosterone 
action of the increased production of progesterone in pregnancy. The administration 
of progesterone has been shown to increase aldosterone production in normal persons 
(refs. 18, 19) and in subjects with normal pregnancy as well as in patients with a 
pregnancy terminated by intra-uterine fetal deathzO. Jones et a1.l demonstrated a 
direct correlation between aldosterone secretion and urinary pregnanediol excretion 
in pregnancy. It has been suggested that the increase in aldosterone constitutes a 
compensatory mechanism against the antagonism of high levels of progesterone*r. 
The picture may in fact be even more complicated since Ehrlich et a1.21 have published 
data suggesting that progesterone secretion per se may be altered by variations in 
salt intake. In any event, there appears to be a relationship between the high con- 
centration of progesterone and the increased production of aldosterone in human 
pregnancy. However, while the maintenance of normal pregnancy requires progressive 
increases in progesterone production, a positive and quantitative relationship be- 
tween the level of aldosterone production and the duration of gestation would not 
seem to be necessary. 
The role of the renin-angiotensin system in mediating a high aldosterone secre- 
tion rate in pregnancy as reviewed recentlyz2 is uncertain. Plasma renin concentra- 
tion is variably increased, remaining within the normal nonpregnant range in some 
women. An increased level of renin substrate has consistently been found in human 
pregnancy. No significant relationship has been demonstrated in pregnancy between 
plasma aldosterone and either plasma renin, or plasma renin substrate. However, a 
significant correlation between plasma aldosterone and the product of plasma renin 
and renin substrate concentrations has been demonstrated. 
Serial simultaneous measurements of both metabolites in the urine of a pregnant 
woman with primary aldosteronism I7 showed a gradual increase in the ratio of aldo- 
sterone: THA from 0.45 before pregnancy to 1.13 in the eighth month of gestation. This 
change in metabolism does not seem to be related to factors such as binding of aldo- 
sternne to plasma proteins other than albumin, or changes in the metabolic clearance 
rate of aldosterone, which appear to be unaltered in pregnancy23924. 
The increase in urinary excretion of THA observed in our subjects are smaller 
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than the increments reported in the literature for the acid-labile conjugate of aldo- 
sterone. Therefore, although we did not measure the excretion rate of this conjugate 
of aldosterone, our data support the finding of Jones et aL.l and Tait and LittleZ5 who 
reported an altered metabolism of aldosterone in pregnancy, Both groups demonstrat- 
ed an increased conversion of aldosterone to the acid-labile conjugate with a relatively 
decreased formation of THA in pregnant subjects. 
In summary, then, our data suggests that there is a considerable increase in 
THA excretion in most, but not all, subjects during pregnancy. While the increase is 
marked it does not appear to be as great as the increase reported for the excretion of 
the other major aldosterone metabolite, aldosterone IS-glucuronide. 
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